For the year ending 2025-12-31, BOLT had $4,471K increase in cash & cash equivalents over the period. -$39,922K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -33,376 |
| Depreciation and amortization | 1,291 |
| Stock-based compensation expense | 2,782 |
| Accretion of discount on marketable securities | 670 |
| Gain on sale of fixed assets | 288 |
| Asset impairment | 0 |
| Non-cash lease expense | 2,526 |
| Prepaid expenses and other assets | -76 |
| Accounts payable and accrued expenses | -5,430 |
| Operating lease liabilities, net | -2,251 |
| Deferred revenue | -4,642 |
| Other long-term liabilities | 132 |
| Net cash used in operating activities | -39,850 |
| Purchase of property and equipment | 72 |
| Proceeds from sales of property and equipment | 963 |
| Purchases of marketable securities | 29,016 |
| Maturities of marketable securities | 72,427 |
| Net cash provided by investing activities | 44,302 |
| Proceeds from issuance of common stock | 19 |
| Net cash provided by financing activities | 19 |
| Net increase (decrease) in cash | 4,471 |
| Cash, cash equivalents and restricted cash at beginning of year | 8,970 |
| Cash, cash equivalents and restricted cash at end of period | 13,441 |
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)